Bourama Traoré, Merepen A. Guindo, Drissa Konaté, Fousseyni Kané, Nathan C. Incandela, Abdouramane Traore, Salimata Kanté, Mariam Sidibé, Bourama Keita, Fatoumata Kasse, Karamoko Tangara, Dramane Diallo, Issoufi Y. Maiga, Salif Thiam, Abdourhamane Cisse, Khatry M. Siby, Abdoul R. Dicko, Mariam Goita, Diakaridia Kone, Mamadou Diallo, Modibo Traore, Yaya I. Coulibaly, Mahamadou Diakité, Seydou Doumbia, Housseini Dolo, Saidou Balam
{"title":"马里巴马科 SARS-CoV-2 抗体血清流行率及相关因素：2022 年 9 月基于人口的横断面研究。","authors":"Bourama Traoré, Merepen A. Guindo, Drissa Konaté, Fousseyni Kané, Nathan C. Incandela, Abdouramane Traore, Salimata Kanté, Mariam Sidibé, Bourama Keita, Fatoumata Kasse, Karamoko Tangara, Dramane Diallo, Issoufi Y. Maiga, Salif Thiam, Abdourhamane Cisse, Khatry M. Siby, Abdoul R. Dicko, Mariam Goita, Diakaridia Kone, Mamadou Diallo, Modibo Traore, Yaya I. Coulibaly, Mahamadou Diakité, Seydou Doumbia, Housseini Dolo, Saidou Balam","doi":"10.1111/irv.13343","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The sero-epidemiological characteristics of SARS-CoV-2 infections in Mali are not yet well understood. This study assessed SARS-CoV-2 antibody seroprevalence and factors associated with antibody responses in the general population of Bamako, the capital city and epicenter of COVID-19, to assess the magnitude of the pandemic and contribute to control strategy improvements in Mali.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A cross-sectional survey was conducted in September 2022 to collect sociodemographic information, clinical characteristics, comorbid factors, and blood samples. ELISA was performed to determine anti-Spike (anti-S) and anti-RBD antibody levels. A total of 3601 participants were enrolled in REDCap. R-Studio was used for the statistical analysis. The chi-squared (χ<sup>2</sup>) test was used to compare the proportions across different groups. Logistic regression models were used to elucidate factors associated with antibody responses.</p>\n </section>\n \n <section>\n \n <h3> Result</h3>\n \n <p>The sex ratio for female-to-male was 3.6:1. The most representative groups were the 20–29-year-olds (28.9%, <i>n</i> = 1043) and the 30–39-year-olds (26.9%, <i>n</i> = 967). The COVID-19 vaccine coverage among the participants was 35.8%, with vaccines from Covishield AstraZeneca (13.4%), Johnson & Johnson (16.7%), Sinovac (3.9%), and BioNTech Pfizer (1.8%). Overall, S protein and RBD antibody seroprevalences were remarkably high in the study population (98% and 97%, respectively). Factors such as youth (1–9 years old) and male sex were associated with lower SARS-CoV-2 antibody responses, whereas COVID-19 vaccinations were associated with increased antibody responses.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This serosurvey demonstrated the high seroprevalence of SARS-CoV-2 antibodies and highlighted the factors influencing antibody responses, while clearly underlining an underestimation of the pandemic in Mali.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 7","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300109/pdf/","citationCount":"0","resultStr":"{\"title\":\"Seroprevalence of SARS-CoV-2 Antibodies and Associated Factors in Bamako, Mali: A Population-Based Cross-Sectional Study in September 2022\",\"authors\":\"Bourama Traoré, Merepen A. Guindo, Drissa Konaté, Fousseyni Kané, Nathan C. Incandela, Abdouramane Traore, Salimata Kanté, Mariam Sidibé, Bourama Keita, Fatoumata Kasse, Karamoko Tangara, Dramane Diallo, Issoufi Y. Maiga, Salif Thiam, Abdourhamane Cisse, Khatry M. Siby, Abdoul R. Dicko, Mariam Goita, Diakaridia Kone, Mamadou Diallo, Modibo Traore, Yaya I. Coulibaly, Mahamadou Diakité, Seydou Doumbia, Housseini Dolo, Saidou Balam\",\"doi\":\"10.1111/irv.13343\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>The sero-epidemiological characteristics of SARS-CoV-2 infections in Mali are not yet well understood. This study assessed SARS-CoV-2 antibody seroprevalence and factors associated with antibody responses in the general population of Bamako, the capital city and epicenter of COVID-19, to assess the magnitude of the pandemic and contribute to control strategy improvements in Mali.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A cross-sectional survey was conducted in September 2022 to collect sociodemographic information, clinical characteristics, comorbid factors, and blood samples. ELISA was performed to determine anti-Spike (anti-S) and anti-RBD antibody levels. A total of 3601 participants were enrolled in REDCap. R-Studio was used for the statistical analysis. The chi-squared (χ<sup>2</sup>) test was used to compare the proportions across different groups. Logistic regression models were used to elucidate factors associated with antibody responses.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Result</h3>\\n \\n <p>The sex ratio for female-to-male was 3.6:1. The most representative groups were the 20–29-year-olds (28.9%, <i>n</i> = 1043) and the 30–39-year-olds (26.9%, <i>n</i> = 967). The COVID-19 vaccine coverage among the participants was 35.8%, with vaccines from Covishield AstraZeneca (13.4%), Johnson & Johnson (16.7%), Sinovac (3.9%), and BioNTech Pfizer (1.8%). Overall, S protein and RBD antibody seroprevalences were remarkably high in the study population (98% and 97%, respectively). Factors such as youth (1–9 years old) and male sex were associated with lower SARS-CoV-2 antibody responses, whereas COVID-19 vaccinations were associated with increased antibody responses.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This serosurvey demonstrated the high seroprevalence of SARS-CoV-2 antibodies and highlighted the factors influencing antibody responses, while clearly underlining an underestimation of the pandemic in Mali.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13544,\"journal\":{\"name\":\"Influenza and Other Respiratory Viruses\",\"volume\":\"18 7\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300109/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Influenza and Other Respiratory Viruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/irv.13343\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13343","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Seroprevalence of SARS-CoV-2 Antibodies and Associated Factors in Bamako, Mali: A Population-Based Cross-Sectional Study in September 2022
Background
The sero-epidemiological characteristics of SARS-CoV-2 infections in Mali are not yet well understood. This study assessed SARS-CoV-2 antibody seroprevalence and factors associated with antibody responses in the general population of Bamako, the capital city and epicenter of COVID-19, to assess the magnitude of the pandemic and contribute to control strategy improvements in Mali.
Methods
A cross-sectional survey was conducted in September 2022 to collect sociodemographic information, clinical characteristics, comorbid factors, and blood samples. ELISA was performed to determine anti-Spike (anti-S) and anti-RBD antibody levels. A total of 3601 participants were enrolled in REDCap. R-Studio was used for the statistical analysis. The chi-squared (χ2) test was used to compare the proportions across different groups. Logistic regression models were used to elucidate factors associated with antibody responses.
Result
The sex ratio for female-to-male was 3.6:1. The most representative groups were the 20–29-year-olds (28.9%, n = 1043) and the 30–39-year-olds (26.9%, n = 967). The COVID-19 vaccine coverage among the participants was 35.8%, with vaccines from Covishield AstraZeneca (13.4%), Johnson & Johnson (16.7%), Sinovac (3.9%), and BioNTech Pfizer (1.8%). Overall, S protein and RBD antibody seroprevalences were remarkably high in the study population (98% and 97%, respectively). Factors such as youth (1–9 years old) and male sex were associated with lower SARS-CoV-2 antibody responses, whereas COVID-19 vaccinations were associated with increased antibody responses.
Conclusion
This serosurvey demonstrated the high seroprevalence of SARS-CoV-2 antibodies and highlighted the factors influencing antibody responses, while clearly underlining an underestimation of the pandemic in Mali.
期刊介绍：
Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases.
Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
